MicroRNA-199b Deregulation Shows Oncogenic Properties and Promising Clinical Value as Circulating Marker in Locally Advanced Rectal Cancer Patients
Authors:
- Andrea SantosASAndrea Santos
- Ion CristóbalICIon Cristóbal
- Jaime RubioJRJaime Rubio
- Cristina CaramésCCCristina Caramés
- Melani LuqueMLMelani Luque
- Marta Sanz-AlvarezMSMarta Sanz-Alvarez
- Miriam Morales-GallegoMMMiriam Morales-Gallego
- Juan Madoz-GúrpideJMJuan Madoz-Gúrpide
- Federico RojoFRFederico Rojo
- Jesús García-FoncillasJesús García-Foncillas
Open Access
- 17 February 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (4) , 2203
Abstract
The identification of robust prognostic markers still represents a need in locally advanced rectal cancer (LARC). MicroRNAs (miRs) have progressively emerged as promising circulating markers, overcoming some limitations that traditional biopsy comprises. Tissue miR-199b deregulation has been reported to predict outcome and response to neoadjuvant chemoradiotherapy (nCRT) in LARC, and was also found to be associated with disease progression in colorectal cancer. However, its biological and clinical relevance remains to be fully clarified. Thus, we observed here that miR-199b regulates cell migration, aggressiveness, and cell growth, and inhibits colonosphere formation and induces caspase-dependent apoptosis. Moreover, miR-199b expression was quantified by real-time PCR in plasma samples from LARC patients and its downregulation was observed in 22.7% of cases. This alteration was found to be associated with higher tumor size (p = 0.002) and pathological stage (p = 0.020) after nCRT. Notably, we observed substantially lower global miR-199b expression associated with patient downstaging (p = 0.009), as well as in non-responders compared to those cases who responded to nCRT in both pre- (p = 0.003) and post-treatment samples (p = 0.038). In concordance, we found that miR-199b served as a predictor marker of response to neoadjuvant therapy in our cohort (p = 0.011). Altogether, our findings here demonstrate the functional relevance of miR-199b in this disease and its potential value as a novel circulating marker in LARC.Keywords
Funding Information
- Instituto de Salud Carlos III FEDER (PI18/00382, PI16/01468)
This publication has 54 references indexed in Scilit:
- MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in MedulloblastomaPLOS ONE, 2009
- Pathologic Predictors of Microsatellite Instability in Colorectal CancerAmerican Journal of Surgical Pathology, 2009
- MicroRNA Expression Profiling in Prostate CancerCancer Research, 2007
- Rac1‐induced cell migration requires membrane recruitment of the nuclear oncogene SETThe EMBO Journal, 2007
- MicroRNA Signatures in Human CancersNature Reviews Cancer, 2006
- Notch Pathway Inhibition Depletes Stem-like Cells and Blocks Engraftment in Embryonal Brain TumorsCancer Research, 2006
- Reporting Recommendations for Tumor Marker Prognostic StudiesJournal of Clinical Oncology, 2005
- A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2005
- MicroRNA Gene Expression Deregulation in Human Breast CancerCancer Research, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001